Exploring RdRp–remdesivir interactions to screen RdRp inhibitors for the management of novel coronavirus 2019-nCoV

References

• Y. Jin, H. Yang, W. Ji, W. Wu, S. Chen, W. Zhang, and G. Duan, Virology, epidemiology, pathogenesis, and control of COVID-19, Viruses 12 (2020), pp. 372.
   PubMed Web of Science ®Google Scholar
• C. Wu, Y. Liu, Y. Yang, P. Zhang, W. Zhong, Y. Wang, Q. Wang, Y. Xu, M. Li, and X. Li, Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods, Acta Pharm. Sin. B 10 (2020), pp. 766–788.
   PubMed Web of Science ®Google Scholar
• C. Harrison, Coronavirus puts drug repurposing on the fast track, Nature Biotechnol. 38 (2020), pp. 379–381.
   Web of Science ®Google Scholar
• M.P. Lythgoe and P. Middleton, Ongoing clinical trials for the management of the COVID-19 pandemic, Trends Pharmacol. Sci. 41 (2020), pp. 363–382.
   PubMed Web of Science ®Google Scholar
• I.F.-N. Hung, K.-C. Lung, E.Y.-K. Tso, R. Liu, T.W.-H. Chung, M.-Y. Chu, -Y.-Y. Ng, J. Lo, J. Chan, and A.R. Tam, Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: An open-label, randomised, phase 2 trial, Lancet 395 (2020), pp. 1695–1704.
   PubMed Web of Science ®Google Scholar
• M. Costanzo, M.A.R. De Giglio, and G.N. Roviello, SARS-CoV-2: Recent reports on antiviral therapies based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and other drugs for the treatment of the new coronavirus, Curr. Med. Chem. 27 (2020), pp. 4536–4541.
   Google Scholar
• P. Zhai, Y. Ding, X. Wu, J. Long, Y. Zhong, and Y. Li, The epidemiology, diagnosis and treatment of COVID-19, Int. J. Antimicrob. 55 (2020), pp. 105955.
   PubMed Web of Science ®Google Scholar
• P.I. Andersen, A. Ianevski, H. Lysvand, A. Vitkauskiene, V. Oksenych, M. Bjørås, K. Telling, I. Lutsar, U. Dampis, and Y. Irie, Discovery and development of safe-in-man broad-spectrum antiviral agents, Int. J. Infect. Dis. 93 (2020), pp. 268–276.
   PubMed Web of Science ®Google Scholar
• R. Islam, M.R. Parves, A.S. Paul, N. Uddin, M.S. Rahman, A.A. Mamun, M.N. Hossain, M.A. Ali, and M.A. Halim, A molecular modeling approach to identify effective antiviral phytochemicals against the main protease of SARS-CoV-2, J. Biomol. Struct. Dyn. (2020), pp. 1–12. doi:10.1080/07391102.2020.1761883.
   Web of Science ®Google Scholar
• V. Kumar and K. Roy, Development of a simple, interpretable and easily transferable QSAR model for quick screening antiviral databases in search of novel 3C-like protease (3CLpro) enzyme inhibitors against SARS-CoV diseases, SAR QSAR Environ. Res. 31 (2020), pp. 511–526.
   PubMed Web of Science ®Google Scholar
• S.A. Amin, K. Ghosh, S. Gayen, and T. Jha, Chemical-informatics approach to COVID-19 drug discovery: Monte Carlo based QSAR, virtual screening and molecular docking study of some in-house molecules as papain-like protease (PLpro) inhibitors, J. Biomol. Struct. Dyn. (2020), pp. 1–10. doi:10.1080/07391102.2020.1780946.
   Web of Science ®Google Scholar
• Y. Gao, L. Yan, Y. Huang, F. Liu, Y. Zhao, L. Cao, T. Wang, Q. Sun, Z. Ming, and L. Zhang, Structure of RNA-dependent RNA polymerase from 2019-nCoV, a major antiviral drug target, BioRxiv (2020). doi: 10.1101/2020.03.16.993386.
   Google Scholar
• Y.-C. Cao, Q.-X. Deng, and S.-X. Dai, Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence, Travel Med. Infect. Dis. 35 (2020), pp. 101647.
   PubMed Web of Science ®Google Scholar
• A.A. Elfiky, SARS-CoV-2 RNA dependent RNA polymerase (RdRp) targeting: An in silico perspective, J. Biomol. Struct. Dyn. (2020), pp. 1–9. doi:10.1080/07391102.2020.176188.
   Web of Science ®Google Scholar
• K.-T. Choy, A.Y.-L. Wong, P. Kaewpreedee, S.-F. Sia, D. Chen, K.P.Y. Hui, D.K.W. Chu, M.C.W. Chan, P.P.-H. Cheung, and X. Huang, Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro, Antivir. Res. 178 (2020), pp. 104786.
   PubMed Web of Science ®Google Scholar
• E. de Wit, F. Feldmann, J. Cronin, R. Jordan, A. Okumura, T. Thomas, D. Scott, T. Cihlar, and H. Feldmann, Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection, Proc. Natl. Acad. Sci. 117 (2020), pp. 6771–6776.
   PubMed Web of Science ®Google Scholar
• J. Grein, N. Ohmagari, D. Shin, G. Diaz, E. Asperges, A. Castagna, T. Feldt, G. Green, M.L. Green, and F.-X. Lescure, Compassionate use of remdesivir for patients with severe Covid-19, N. Engl. J. Med. 382 (2020), pp. 2327–2336.
   PubMed Web of Science ®Google Scholar
• N. Pala, A. Stevaert, R. Dallocchio, A. Dessì, D. Rogolino, M. Carcelli, V. Sanna, M. Sechi, and L. Naesens, Virtual screening and biological validation of novel influenza virus PA endonuclease inhibitors, ACS Med. Chem. Lett. 6 (2015), pp. 866–871.
   PubMed Web of Science ®Google Scholar
• Y. Gao, L. Yan, Y. Huang, F. Liu, Y. Zhao, L. Cao, T. Wang, Q. Sun, Z. Ming, and L. Zhang, Structure of the RNA-dependent RNA polymerase from COVID-19 virus, Science 368 (2020), pp. 779–782.
   PubMed Web of Science ®Google Scholar
• I. Schomburg, L. Jeske, M. Ulbrich, S. Placzek, A. Chang, and D. Schomburg, The BRENDA enzyme information system–From a database to an expert system, J. Biotechnol. 261 (2017), pp. 194–206.
   PubMed Web of Science ®Google Scholar
• W. Yin, C. Mao, X. Luan, D.-D. Shen, Q. Shen, H. Su, X. Wang, F. Zhou, W. Zhao, and M. Gao, Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir, Science 368 (2020), pp. 1499–1504.
   PubMed Web of Science ®Google Scholar
• A.T. Boraei, P.K. Singh, M. Sechi, and S. Satta, Discovery of novel functionalized 1, 2, 4-triazoles as PARP-1 inhibitors in breast cancer: Design, synthesis and antitumor activity evaluation, Eur J. Med. Chem. 182 (2019), pp. 111621.
   PubMed Web of Science ®Google Scholar
• S. Vilar, G. Cozza, and S. Moro, Medicinal chemistry and the molecular operating environment (MOE): Application of QSAR and molecular docking to drug discovery, Curr. Top. Med. Chem. 8 (2008), pp. 1555–1572.
   PubMed Web of Science ®Google Scholar
• L. Tan, E. Lounkine, and J.R. Bajorath, Similarity searching using fingerprints of molecular fragments involved in protein− ligand interactions, J. Chem. Inf. Model. 48 (2008), pp. 2308–2312.
   PubMed Web of Science ®Google Scholar
• P. Singh and O. Silakari, Molecular dynamics and pharmacophore modelling studies of different subtype (ALK and EGFR (T790M)) inhibitors in NSCLC, SAR QSAR Environ. Res. 28 (2017), pp. 221–233.
   PubMed Web of Science ®Google Scholar
• P.K. Singh and O. Silakari, In silico guided development of imine-based inhibitors for resistance-deriving kinases, J. Biomol. Struct. Dyn. 37 (2019), pp. 2593–2599.
   PubMed Web of Science ®Google Scholar
• C.C.G. Inc, Molecular Operating Environment (MOE), Chemical Computing Group Inc, 1010 Sherbooke St. West, Suite# 910, Montreal, 2016.
   Google Scholar
• N. Pala, F. Esposito, E. Tramontano, P.K. Singh, V. Sanna, M. Carcelli, L.D. Haigh, S. Satta, and M. Sechi, Development of a Raltegravir-based photoaffinity-labeled probe for human immunodeficiency virus-1 integrase capture, ACS Med. Chem. Lett. (2020). doi:10.1021/acsmedchemlett.0c00009.
   Web of Science ®Google Scholar
• J. Dong, N.-N. Wang, Z.-J. Yao, L. Zhang, Y. Cheng, D. Ouyang, A.-P. Lu, and D.-S. Cao, ADMETlab: A platform for systematic ADMET evaluation based on a comprehensively collected ADMET database, J. Cheminf. 10 (2018), pp. 29.
   PubMed Web of Science ®Google Scholar
• P.K. Singh, D. Chaudhari, S. Jain, and O. Silakari, Structure based designing of triazolopyrimidone-based reversible inhibitors for kinases involved in NSCLC, Bioorg. Med Chem. Lett. 29 (2019), pp. 1565–1571.
   PubMed Web of Science ®Google Scholar
• D. Antoine, O. Michielin, and V. Zoete, SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules, Sci. Rep. 7 (2017), pp. 42717.
   PubMed Web of Science ®Google Scholar